Hyundai Bioscience Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jong-Won Choi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Jan 03

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Nov 29

CEO

Jong-Won Choi (57 yo)

no data

Görev süresi

Choi Jong-Won serves as a Co-Chief Executive Officer of Hyundai IT Corp. Choi Jong-Won served as Managing Director of KRPM, Korea Telecom Data, Inc., and Elli Partners. Choi Jong-Won served as Director of...

Hyundai Bioscience Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?

Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty

New major risk - Financial data availability

Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060).

Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion.

Full year 2023 earnings released: ₩365 loss per share (vs ₩402 loss in FY 2022)

New major risk - Share price stability

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

New major risk - Share price stability

Full year 2022 earnings released: ₩402 loss per share (vs ₩543 loss in FY 2021)

Less than half of directors are independent

Vector Inc. (TSE:6058) agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410) for KRW 13.7 billion.

Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA

Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials

Less than half of directors are independent

Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day high: ₩37,100

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

New 90-day high: ₩13,650

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day low: ₩10,150

New 90-day low: ₩10,800

Hyundai Bioscience Co., Ltd. announced that it has received KRW 32 billion in funding from a group of investors

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 32 billion in funding from a group of investors

CEO

Görev süresi